USA Today Article: Frontrunners of the Future
BiomeBank gets included on a list of 'The Best Startups Shaping The Next Era Of Innnovation'
Comments Off on USA Today Article: Frontrunners of the Future
April 15, 2024
LA Weekly Article: Innovating Health Solutions – The People Behind BiomeBank’s Microbiome Therapies
LA weekly covers BiomeBank in this article.
February 24, 2024
Australian Biotech Company Takes Big Step Towards Becoming Global Leader
Media Release: Australian biotech company BiomeBank has successfully secured a multimillion-dollar Federal Government grant that will turbo charge the development and production of microbiome-based therapies.
Comments Off on Australian Biotech Company Takes Big Step Towards Becoming Global Leader
February 18, 2024
BiomeBank’s State-of-the-Art GMP Facility Unveiled in Adelaide
BiomeBank today announced the opening of its new GMP manufacturing facility designed to increase global supply of its approved donor derived microbiome-based therapy and further develop its second-generation therapies.
Comments Off on BiomeBank’s State-of-the-Art GMP Facility Unveiled in Adelaide
November 8, 2023
BiomeBank announces new Chief Operating Officer role
BiomeBank has announced the appointment of Kolby Day to the new position of Chief Operating Officer at the biotech drug development company based in Adelaide, South Australia.
August 22, 2023
BiomeBank announces world first regulatory approval for donor derived microbiome drug
Formal Therapeutic Goods Administration (“TGA”) approval of BiomeBank’s first-generation donor derived microbiome-based therapy.
November 9, 2022
What is the Microbiome?
Page Contents Overview The human body is inhabited by trillions of microscopic organisms including bacteria, viruses, fungi and archaea. Although they’re too small to see with the naked eye, microbes inhabit almost every part of the human body, including on our skin, up our nose and inside our gut. Collectively…
Comments Off on What is the Microbiome?
February 21, 2022
Microbiome medicine accelerated by new partnership between BiomeBank and Hudson Institute
The translation of research into the development of innovative and life-saving microbial therapies is set to transform in Australia through a partnership between Hudson Institute of Medical Research and BiomeBank, a clinical stage microbiome therapeutics company.
Comments Off on Microbiome medicine accelerated by new partnership between BiomeBank and Hudson Institute
January 26, 2022
BiomeBank appoints ex-Ellerston Capital CIO and Blackrock North Asia Director as Chair to accelerate commercialisation strategy
BiomeBank appoints Mr Chris Hall as Chair, effective 17 January 2022. Mr Hall brings over 30 years’ experience and impressive track record of investment management across both public and private markets within APAC. BiomeBank’s Series A funding round anticipated to close in early 2022. Formal Therapeutic Goods Association (“TGA”) approval of…
January 19, 2022